ReCode Therapeutics to Participate in November Conferences
Menlo Park, Calif. – Nov. 10, 2023 – ReCode Therapeutics, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today...
View ArticleLung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas...
Nature Communications The post Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models first appeared on ReCode Therapeutics.
View ArticleSenior/Executive Director, Translational Sciences & Nonclinical Operations
Menlo Park, CA The post Senior/Executive Director, Translational Sciences & Nonclinical Operations first appeared on ReCode Therapeutics.
View ArticleSenior Scientist / Principal Scientist, Cell Biology – Lung Epithelia
Menlo Park, CA The post Senior Scientist / Principal Scientist, Cell Biology – Lung Epithelia first appeared on ReCode Therapeutics.
View ArticleReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel...
– Phase 1 study aims to evaluate safety and tolerability of a single ascending dose of RCT1100 in patients with PCD caused by mutations in the DNAI1 gene – – RCT1100 is the first clinical evaluation of...
View ArticleIntellia Therapeutics and ReCode Therapeutics Announce Strategic...
– Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP)to extend the...
View ArticleReCode Therapeutics to Participate in February Conferences
Menlo Park, Calif. – February 20, 2024 – ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics,...
View ArticleReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy...
– Study will evaluate the safety and tolerability of RCT2100, an inhaled mRNA-based therapy for the 10-13% of CF patients who have Class I mutations in the CFTR gene – – Second clinical-stage candidate...
View ArticleReCode Therapeutics to Participate in May Conferences
Menlo Park, Calif. – May 1, 2024 – ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today...
View ArticleReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of...
Menlo Park, Calif. – May 13, 2024 – ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today...
View ArticleNew Article Published in Science Highlights the Potential of ReCode...
Menlo Park, Calif. – June 13, 2024 – ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics,...
View ArticleReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for...
ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and...
View ArticleLung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas...
Nature Communications The post Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models first appeared on ReCode Therapeutics.
View ArticleReCode Therapeutics to Participate in Upcoming Investor Conferences
Menlo Park, Calif. – September 25, 2024 – ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics,...
View ArticleReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100...
– Phase 1b study will evaluate the safety and tolerability of multiple ascending doses of RCT2100 in people with cystic fibrosis – Menlo Park, Calif. – September 26, 2024 – ReCode Therapeutics, a...
View ArticleReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis...
Menlo Park, Calif. – September 26, 2024 – ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics,...
View ArticleReCode Announces Two Key Additions to Scientific Advisory Board
Drs. Katalin Karikó and Andrew Bellinger bring deep expertise in mRNA and gene correction delivery and development to the advisory board Menlo Park, Calif. – October 1, 2024 – ReCode Therapeutics, a...
View Article